Tricuspid Valve Repair Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Tricuspid Valve Regurgitation, Tricuspid Valve Stenosis), By End Use (Hospitals, Ambulatory Surgical Centers {ASCs}, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 663.69 Million
CAGR (2026-2031)	6.31%
Fastest Growing Segment	Tricuspid Valve Regurgitation
Largest Market	North America
Market Size (2031)	USD 957.96 Million

Market Overview

The Global Tricuspid Valve Repair Market will grow from USD 663.69 Million in 2025 to USD 957.96 Million by 2031 at a 6.31% CAGR. The Global Tricuspid Valve Repair Market consists of medical devices and procedural techniques utilized to reconstruct the tricuspid valve and correct regurgitation without necessitating replacement. Growth is primarily driven by the escalating burden of valvular heart disease within the geriatric demographic. According to the European Society of Cardiology, in 2024, relevant tricuspid regurgitation was estimated to affect 4% of the population over 75 years of age. This substantial patient pool, alongside the increasing preference for minimally invasive transcatheter therapies that reduce recovery times, strongly supports market development.

However, a significant challenge impeding expansion is the inherent anatomical complexity of the tricuspid valve, which complicates device anchoring and visualization during intervention. This difficulty necessitates highly specialized physician training and advanced imaging infrastructure, often limiting procedure availability to major academic centers. Such technical barriers contribute to higher procedural costs and slower adoption rates in community hospital settings, thereby hindering the widespread accessibility required for broader market growth.

Key Market Drivers

Technological breakthroughs in Transcatheter Tricuspid Valve Repair (TTVR) are reshaping the market by providing alternatives to high-risk surgery. Recent regulatory approvals have validated devices that address the complex anatomy of the tricuspid valve, enabling commercialized therapies. According to Edwards Lifesciences, February 2024, in the 'Edwards EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval' press release, approximately 99 percent of patients treated with the device had severe leakage reduced to moderate or less. This clinical efficacy is driving rapid commercial adoption. According to Edwards Lifesciences, October 2024, in the 'Edwards Lifesciences Reports Third Quarter Results' press release, Transcatheter Mitral and Tricuspid Therapies sales grew 73 percent to 91 million dollars, reflecting strong market uptake.

The rising prevalence of tricuspid regurgitation (TR) and heart failure creates a massive unmet need. Often termed the "forgotten valve," TR affects a vast geriatric patient population that historically lacked treatment options due to surgical risks. This disparity between disease burden and intervention rates is a critical catalyst for growth. According to Abbott, April 2024, in the 'Abbott Receives FDA Approval for TriClip' press release, more than 1.6 million people in the U.S. are affected by tricuspid regurgitation. As advanced diagnostics identify more candidates for these newly approved minimally invasive repairs, the market is expanding to accommodate this substantial patient pool.

Download Free Sample Report

Key Market Challenges

The inherent anatomical complexity of the tricuspid valve constitutes a substantial barrier to the expansion of the Global Tricuspid Valve Repair Market. Unlike other cardiac valves, the tricuspid valve is characterized by fragile leaflets and a highly variable structure, often presenting with three or more leaflets and a large, non-planar annulus. This intricacies significantly complicate the anchoring of repair devices and necessitate exceptional visualization capabilities during interventions. Consequently, effective repair procedures require highly specialized physician training and advanced imaging infrastructure, such as intraprocedural transesophageal echocardiography. These stringent technical demands effectively limit the availability of these procedures to major academic medical centers, preventing their widespread adoption in community hospitals where such resources and expertise may be scarce.

This concentration of service availability creates a bottleneck that directly impedes market growth. Although the prevalence of valvular disease is high, the technical difficulty associated with the tricuspid anatomy results in a procedural volume that is disproportionately low relative to the patient population. According to the Society of Thoracic Surgeons, in 2024, national database trends indicated that isolated tricuspid valve surgeries remain a limited intervention, with only over 2,000 cases performed annually in the United States. This low utilization rate demonstrates how technical challenges and the resulting procedural exclusivity are stalling the broader accessibility and commercial scalability of repair therapies.

Key Market Trends

The integration of AI-enhanced multimodality imaging is rapidly emerging as a critical trend, directly addressing the visualization challenges associated with the tricuspid valve's complex anatomy. To overcome the difficulties of intra-procedural guidance, manufacturers are embedding artificial intelligence into echocardiography systems to automate view recognition and anatomical quantification. According to Siemens Healthineers, August 2024, in the 'Siemens Healthineers Announces FDA Clearance of Cardiovascular Ultrasound System' press release, the newly cleared ACUSON Origin system features AI Assist capabilities that demonstrated a 99 percent accuracy rate for view classification and Doppler placement. This technological advancement reduces operator variability and streamlines workflow, thereby facilitating the precise anchoring required for effective transcatheter repair.

Concurrently, the acceleration of pivotal clinical trials and post-market registries is generating the robust long-term evidence needed to standardize repair protocols and support wider adoption. As the market moves beyond early feasibility, the release of mature data from large-scale studies is validating the durability of transcatheter edge-to-edge repair in diverse, real-world patient populations. According to the American College of Cardiology, August 2024, in the 'Real-World 1-Year Results of Tricuspid Edge-to-Edge Repair From the bRIGHT Study' report, the Abbott TriClip system demonstrated sustained efficacy with 81 percent of patients achieving tricuspid regurgitation of moderate or less at one year. These positive clinical outcomes are instrumental in building physician confidence and securing the reimbursement necessary for market expansion.

Segmental Insights

The Tricuspid Valve Regurgitation segment represents the fastest-growing area of the Global Tricuspid Valve Repair Market. This rapid expansion is primarily driven by the increasing incidence of functional regurgitation among an aging global population and the emergence of viable transcatheter interventions. Historically, high surgical risks limited treatment options for these patients, often leaving the condition unmanaged. However, recent milestones, including approvals by the U.S. Food and Drug Administration (FDA) for dedicated transcatheter repair devices, have transformed the clinical landscape. These regulatory authorizations now allow for minimally invasive procedures in high-risk patients who were formerly restricted to medical therapy, thereby significantly widening the addressable market.

Regional Insights

North America maintains a dominant position in the Global Tricuspid Valve Repair Market, primarily driven by the high prevalence of tricuspid regurgitation and a robust healthcare infrastructure. This market leadership is significantly reinforced by rigorous yet supportive regulatory frameworks, such as the approvals granted by the U.S. Food and Drug Administration (FDA) for advanced transcatheter repair systems. Additionally, the region benefits from the strong presence of major medical device manufacturers and favorable reimbursement policies which facilitate patient access to these innovative therapies. These factors collectively secure North America's status as the leading regional market.

Recent Developments

• In October 2024, Jenscare Scientific released the one-year follow-up results of the TRAVEL II study for its LuX-Valve Plus system at the Transcatheter Cardiovascular Therapeutics (TCT) conference. The multicenter trial evaluated the long-term safety and efficacy of the transcatheter tricuspid valve replacement device in patients with severe tricuspid regurgitation and high surgical risk. The findings indicated a high device success rate and a low incidence of composite safety events, along with significant and sustained improvements in tricuspid regurgitation grade and clinical functional status at one year post-procedure.
• In June 2024, CroíValve presented positive six-month outcomes from the TANDEM I first-in-human clinical trial of its Duo Tricuspid Coaptation Valve System at the New York Valves 2024 conference. The study data highlighted that the system, which works in tandem with the native valve to restore function, successfully reduced tricuspid regurgitation to moderate or less in over 85% of patients. The results also demonstrated significant improvements in patient symptoms and quality of life, supporting the device's safety and efficacy as a novel repair solution for severe tricuspid valve disease.
• In April 2024, Abbott obtained approval from the U.S. FDA for its TriClip Transcatheter Edge-to-Edge Repair (TEER) system. This device is specifically designed to treat tricuspid regurgitation by clipping the valve leaflets together to reduce the backflow of blood. The approval was based on data from the TRILUMINATE Pivotal trial, which showed that the system significantly improved the quality of life and reduced the severity of TR in patients who remained symptomatic despite medical therapy, offering a minimally invasive repair option for this high-risk patient population.
• In February 2024, Edwards Lifesciences announced that it had received approval from the U.S. Food and Drug Administration (FDA) for the EVOQUE tricuspid valve replacement system. This approval marked the device as the first transcatheter therapy authorized in the United States for the treatment of tricuspid regurgitation (TR). The regulatory decision was supported by positive results from the TRISCEND II pivotal trial, which demonstrated the system's superiority over optimal medical therapy alone in improving health status and eliminating regurgitation in patients with symptomatic severe TR.

Key Market Players

• Medtronic Plc
• Edwards Lifesciences Corporation
• LivaNova Plc
• Abbott Laboratories Inc.
• Corcym UK Limited
• Micro Interventional Devices, Inc.
• 4C Medical Technologies, Inc.
• Venus Medtech (Hangzhou) Inc.
• TRiCares GmbH
• Trisol Medical

By Indication	By End Use	By Region
Tricuspid Valve Regurgitation Tricuspid Valve Stenosis	Hospitals Ambulatory Surgical Centers {ASCs} Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Tricuspid Valve Repair Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Tricuspid Valve Repair Market, By Indication:

• Tricuspid Valve Regurgitation
• Tricuspid Valve Stenosis

• Tricuspid Valve Repair Market, By End Use:

• Hospitals
• Ambulatory Surgical Centers {ASCs}
• Others

• Tricuspid Valve Repair Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE